An exercise in expectations: Exenatide III

  In August 2017, the results of a Phase II double-blind, placebo controlled clinical trial investigating whether the diabetes drug Exenatide (aka Bydureon) can be repurposed for the treatment of Parkinson’s were published. Despite the fact that the study did not meet most of its end points, the Parkinson’s community got very excited about one … Continue reading An exercise in expectations: Exenatide III

Exciting Exenatide Exosomes

  Recent analysis of blood samples collected during the Phase II clinical trial of Exenatide in Parkinson’s has uncovered a very interesting finding that could have major implications for not only Parkinson’s, but for many different neurological conditions. Exenatide is a treatment that helps to control glucose levels in people with diabetes. More recently, however, … Continue reading Exciting Exenatide Exosomes

What do you do with a problem like Exenatide?

At 23:30 on the 3rd August 2017, the results of a phase II clinical trial investigating the use of a Glucagon-like peptide-1 receptor (GLP-1R) agonist called Exenatide (Bydureon) in Parkinson’s were published the Lancet journal website. The findings of the study were very interesting. And after years of failed trials, the Parkinson’s community finally had … Continue reading What do you do with a problem like Exenatide?